TABLE 3.
Distribution of vaccine types of noninvasive S. pneumoniae isolates according to subject age group during 2009 to 2012 in the United States
| Vaccine typea by age group (yrs) | No. (%) by yr |
No. (%) for all yrs | |||
|---|---|---|---|---|---|
| 2009 | 2010 | 2011 | 2012 | ||
| PCV7 | 25 (4.6) | 38 (5.5) | 47 (5.0) | 37 (5.0) | 147 (5.0) |
| 18–49 | 7 (28.0) | 9 (23.7) | 16 (34.0) | 14 (37.8) | 46 (31.3) |
| 50–64 | 11 (44.0) | 10 (26.3) | 16 (34.0) | 7 (18.9) | 44 (29.9) |
| ≥65 | 7 (28.0) | 19 (50.0) | 15 (31.9) | 16 (43.2) | 57 (38.8) |
| PCV13 | 195 (35.5) | 232 (33.7) | 319 (33.8) | 210 (28.2) | 956 (32.7) |
| 18–49 | 64 (32.8) | 74 (31.9) | 118 (37.0) | 68 (32.4) | 324 (33.9) |
| 50–64 | 58 (29.7) | 82 (35.3) | 99 (31.0) | 79 (37.6) | 318 (33.3) |
| ≥65 | 73 (37.4) | 76 (32.8) | 102 (32.0) | 63 (30.0) | 314 (32.8) |
| PPSV23-nonPCV13 | 134 (24.4) | 172 (25.0) | 229 (24.3) | 197 (26.4) | 732 (25.0) |
| 18–49* | 53 (39.6) | 65 (37.8) | 75 (32.8) | 59 (29.4) | 252 (34.4) |
| 50–64 | 45 (33.6) | 49 (28.5) | 77 (33.6) | 75 (38.1) | 246 (33.6) |
| ≥65 | 36 (26.9) | 58 (33.7) | 77 (33.6) | 63 (32.0) | 234 (32.0) |
| Nonvaccine | 207 (37.7) | 271 (39.4) | 374 (39.6) | 324 (43.4) | 1,176 (40.2) |
| 18–49 | 63 (30.4) | 99 (36.5) | 119 (31.9) | 106 (32.7) | 387 (32.9) |
| 50–64 | 68 (32.9) | 88 (32.5) | 128 (34.2) | 109 (33.6) | 393 (33.4) |
| ≥65 | 76 (36.7) | 84 (31.0) | 127 (34.0) | 109 (33.6) | 396 (33.7) |
| Nontypeable | 13 (2.4) | 13 (1.9) | 22 (2.3) | 15 (2.0) | 63 (2.2) |
| 18–49 | 5 (38.5) | 3 (23.1) | 8 (36.4) | 4 (26.7) | 20 (31.7) |
| 50–64* | 7 (53.8) | 6 (46.2) | 7 (31.8) | 2 (13.3) | 22 (34.9) |
| ≥65* | 1 (7.7) | 4 (30.8) | 7 (31.8) | 9 (60.0) | 21 (33.3) |
| All | 549 (100.0) | 688 (100.0) | 944 (100.0) | 746 (100.0) | 2,927 (100.0) |
a
Differences in serotype prevalence rates over time were assessed by calculating the P values by the chi-square test for trends using Epi Info, version 7.1.1.14. *, calculated P values were <0.05 and were considered statistically significant. “Nonvaccine” indicates those strains not present in the three vaccines available in the United States.